[BostonCard]

I think the safety risks are understated.  They saw multiple grade 3 systemic reactions in a sample size of 15 at the highest dose, and one grade 3 reaction at the middle dose.  It will be less common at lower doses, but I would expect to see some cases as the numbers are increased, probably even at the 50 µg dose they are moving to phase 2.  It is a bit concerning that they didn't advance the 25 µg dose forward.

BC

[BostonCard]

I think the safety risks are understated.  They saw multiple grade 3 systemic reactions in a sample size of 15 at the highest dose, and one grade 3 reaction at the middle dose.  It will be less common at lower doses, but I would expect to see some cases as the numbers are increased, probably even at the 50 µg dose they are moving to phase 2.  It is a bit concerning that they didn't advance the 25 µg dose forward.

BC